Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study

Melbourne, Australia, Could 08, 2026 (GLOBE NEWSWIRE) — HIGHLIGHTS

• Amplia and ANZGOG enter into settlement to conduct a medical research in ovarian most cancers evaluating narmafotinib together with standard-of-care chemotherapy
• Ovarian most cancers represents a serious goal for FAK inhibition remedy primarily based on usually greater ranges of FAK expression and fibrous nature of tumour
• The research to enrol sufferers with high-grade serous ovarian most cancers (HGSOC) who haven’t responded to platinum-based chemotherapy previous to surgical procedure
• Study focus is security and exploring potential to enhance post-surgical outcomes; biomarker assortment will additional characterize mechanism of motion of narmafotinib

{{DATELINECITY_DATE_GLOBENEWSWIRE_BUG}Amplia Therapeutics Restricted (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Firm”), and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) pronounces that they’ve entered into an settlement to conduct a brand new medical research investigating the Firm’s lead drug narmafotinib in ovarian most cancers. Narmafotinib is a best-in-class FAK inhibitor at the moment present process medical growth in pancreatic most cancers the place it’s displaying promising efficacy mixed with good tolerability.

The research is an investigator-initiated medical trial led by Dr Gwo Yaw Ho of Monash Well being and Monash College, and sponsored and coordinated by ANZGOG, a global cooperative medical trials community spanning main hospitals throughout Australia and New Zealand. The research is anticipated to enroll roughly 15–20 sufferers with high-grade serous ovarian most cancers (HGSOC) who show poor response to up-front standard-of-care platinum-based chemotherapy previous to deliberate interval debulking surgical procedure.

The trial, to be referred to as the PRROSE trial, will consider the protection of narmafotinib together with standard-of-care chemotherapy (carboplatin and paclitaxel) on this affected person inhabitants. Roughly one in 5 ovarian most cancers sufferers don’t reply adequately to preliminary chemotherapy, limiting their capability to endure surgical procedure and contributing to poor medical outcomes. This research is designed to deal with this vital unmet medical want.

The research will subsequently additionally discover whether or not the addition of narmafotinib can enhance the proportion of sufferers eligible for profitable surgical resection. Intensive tissue and blood biomarkers can be examined for perception into narmafotinib’s mechanism of motion to additional enrich knowledge offered from the research.

Dr Chris Burns, CEO and Managing Director of Amplia, commented, “We’re very happy to be collaborating with ANZGOG and Dr Ho on this promising research. Based mostly on the compelling organic rationale for the potential of FAK inhibitors in ovarian most cancers, a medical program on this indication is clearly warranted. Sufferers with ovarian most cancers who don’t reply to preliminary chemotherapy have very restricted remedy choices and this research will present a possibility to evaluate whether or not narmafotinib can enhance outcomes for these sufferers. This trial additionally represents an necessary step in broadening the medical utility of our FAK inhibitor program.”

Dr Gwo Yaw Ho, Lead Investigator, mentioned, “This research displays the energy of ANZGOG’s collaborative medical trials community and its capability to deliver collectively main medical investigators to deal with areas of excessive unmet want in gynecological cancers. This trial builds on ANZGOG’s established functionality to design and ship rigorous, doubtlessly practice-changing medical analysis throughout Australia and New Zealand. The research is underpinned by a dedication to translating promising scientific approaches, comparable to Amplia’s, into well-conducted medical trials that may generate significant proof to tell future remedy choices for girls with ovarian most cancers.”

This ASX announcement was authorized and licensed for launch by the Board of Amplia Therapeutics.

About Amplia Therapeutics Restricted

Amplia Therapeutics Restricted is an Australian pharmaceutical firm advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for most cancers and fibrosis. FAK is an more and more necessary goal within the discipline of most cancers and Amplia has a selected growth focus in fibrotic cancers comparable to pancreatic and ovarian most cancers. FAK additionally performs a big function in quite a few persistent illnesses, comparable to idiopathic pulmonary fibrosis (IPF). For extra info go to www.ampliatx.com and comply with Amplia on X (@ampliatx) and LinkedIn.

Concerning the Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG is the height nationwide gynecological most cancers analysis group in Australia and New Zealand. It’s greater than 1650 members work in hospitals, analysis establishments, universities, authorities, the non-profit sector, and trade. Members embody surgeons, physicians, radiation oncologists, psychologists, social staff, nurses, trial coordinators, pure researchers, allied well being professionals and most cancers shoppers who’re primarily based in all states of Australia and areas in New Zealand. ANZGOG’s imaginative and prescient is Advancing analysis, saving lives and its mission is to enhance outcomes and high quality of life for everybody with a lived expertise of gynecological most cancers by conducting and selling medical trials and multidisciplinary analysis. For extra info, go to www.anzgog.org.au and comply with ANZGOG on LinkedIn

About Narmafotinib

Narmafotinib (AMP945) is the corporate’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic most cancers and a drug goal gaining rising consideration for its function in strong tumors. The drug, which is a extremely potent and selective inhibitor of FAK, has proven promising knowledge in a variety of preclinical most cancers research. Narmafotinib is at the moment present process a medical trial (the ACCENT trial) the place it’s dosed together with the chemotherapies gemcitabine and Abraxane in first-line sufferers with superior pancreatic most cancers. The trial has achieved its desired final result in reaching a response fee of 36%, superior to chemotherapy alone, and a mOS of 11.1 months has been reported. A second trial – AMPLICITY – is being run at websites in Australia investigating the mix of narmafotinib with the chemotherapy FOLFIRINOX in superior pancreatic most cancers sufferers.